<img src="https://secure.24-astute.com/796183.png" style="display:none;">

Our People

Dr. Torsten Neuefeind

CEO
Torsten founded Proteros based on the belief that structural biology services would become a key market requirement in the future of industrial Drug Discovery.
 
Torsten set up the company based on a McKinsey &Co awarded business plan and the experience of his PhD thesis in the lab of Nobel prize winner Prof. R. Huber at the Max-Planck Institute of Biochemistry, Munich as well as at Bayer AG. He set up the company structure, including high performance teams, a supervisory board and involvement of Prof. Huber as a co-founder and scientific advisor. He continues to manage the financing of the growth of the company in all stages and developed the business in Europe, US and Japan and made Proteros a renowned market leader in its segment, awarded as one of Bavaria’s best innovative growth companies. 
Torsten_bw
 
Under Torsten’s guidance, the business has grown to serve most of the Top20 Big Pharma Companies, numerous midsize Pharma and more than 200 Biotech and virtual Biotech companies with a strong presence in the US, including a partnership with a US Venture Capital firm, resulting in a successful exit of a jointly funded company, worth several hundred million ‘Bio-Dollars’.Proteros today is a premier provider of structure accelerated early Drug Discovery services, with a clear focus on scientific excellence and the most challenging drug targets and is a highly regarded brand in the community.

Torsten holds a degree in chemistry and a PhD with summa cum laude from the Technical University Munich including business courses e.g. from INSEAD. He serves on various Boards and is located in Munich.

Prof. Dr. Robert Huber

Co-Founder

One of the pioneers in structural biology is Prof. Drs. mult. Robert Huber, who over decades contributed to the development of protein x-ray crystallography at the Max-Planck Institute of Biochemistry, Martinsried. His contributions culminated in becoming awarded the Nobel Prize in 1988 for the elucidation of the photosynthetic reaction center. When Proteros started its business in 2000 as the first service provider for structural biology services,  Prof. Huber was willing to act as a co-founder and to support Proteros with his scientific expertise, reputation and single proprietary technologies, licensed from the Max Planck society.

Robert Huber-2

Dr. Ashiq H. Khan

EXECUTIVE VICE PRESIDENT - (BD EMEA)

Ashiqs leads Proteros' global commercial strategy and business development, driving market expansion, launching new ventures, and cultivating strategic partnerships. His leadership has been instrumental in advancing Proteros' mission to deliver innovative solutions that accelerate drug discovery.

With a robust background in protein structure-based drug discovery and biologics, Ashiq has a proven track record of leading high-impact initiatives and fostering collaboration across the life sciences industry. His customer-focused leadership style, emphasizing innovation and operational excellence, aligns seamlessly with Proteros' commitment to providing unparalleled value to its clients.

Ashiq-1
 

Ashiq earned his Ph.D. in Molecular Neurobiology from the University of Cologne, Germany, conducting significant research at Harvard University, USA. He completed his postdoctoral training at Yale University, USA, and further enhanced his business acumen through studies at INSEAD. Beyond his role at Proteros, Ashiq is known for his strategic vision and dedication to advancing the field of drug discovery, consistently contributing to the industry's growth and innovation.

Lara Kurth 

Head of Finance

Lara leads Proteros´ Finance function and is responsible for shaping and overseeing the Financial Strategy, Accounting, Controlling and Tax functions at Proteros. Lara brings a broad range of experience within finance. Before joining Proteros in January 2024, she acted as Vice President at a global Investment Bank, advising mid-sized companies on Mergers & Acquisitions transactions in the Healthcare sector. Prior to that, she was part of KPMG’s M&A advisory team.

Lara holds a Master degree in Accounting and Finance from the University St. Gallen, Switzerland and a B.A. in Business and Economics from the University of Basel, Switzerland.

LinkedIn

 

Lara_266-jpg

Prof. Eric P. Pâques 

Board Member

Eric P. Pâques is Non-Executive Chairman of the Supervisory Board of Proteros Biostructure GmbH (Munich, Germany) since 2014, chairman of the Board of Directors of Novadip Biosciences (Belgium) and Board member of Epics Therapeutics (Belgium) and of PL Bioscience (Germany) as well as of several academic and charity organizations. He was Independent Director of INC Research Inc., later Syneos Health, (USA), and Vice-Chairman of the Supervisory Board of the Grünenthal Group (Germany). He served more than 35 years in management positions in the pharmaceutical industry, thereof 20 years as General Manager / CEO of the Grünenthal Group. He is professor at the RWTH-Aachen University (Germany) and holds a Master degree and a PhD in Chemistry (University of Louvain, Belgium).

LinkedIn

 

Eric-P-Pâques-1